| pubmed-article:2011577 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0033147 | lld:lifeskim |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0450127 | lld:lifeskim |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0034819 | lld:lifeskim |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:2011577 | lifeskim:mentions | umls-concept:C0038952 | lld:lifeskim |
| pubmed-article:2011577 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2011577 | pubmed:dateCreated | 1991-5-6 | lld:pubmed |
| pubmed-article:2011577 | pubmed:abstractText | High-affinity interleukin 2 receptors (IL-2Rs) are expressed by T cells activated in response to foreign histocompatibility antigens but not by normal resting T cells. To exploit this difference in IL-2R expression, anti-Tac-M, a murine monoclonal antibody specific for the IL-2R alpha chain, was used to inhibit organ allograft rejection. However, the use of murine anti-Tac as an immunosuppressive agent was limited by neutralization by human anti-murine antibodies and by weak recruitment of effector functions. To circumvent these difficulties, a humanized antibody to the IL-2R, anti-Tac-H, was prepared. This molecule is human with the exception of the hypervariable segments, which are retained from the mouse. In vivo survival of anti-Tac-H is 2.5-fold longer than simultaneously administered anti-Tac-M (terminal t1/2, 103 hr vs. 38 hr). In addition, anti-Tac-H is less immunogenic than anti-Tac-M when administered to cynomolgus monkeys undergoing heterotopic cardiac allografting. Specifically, all monkeys treated with anti-Tac-M developed measurable anti-anti-Tac-M levels by day 15 (mean onset, 11 days). In contrast, none of the animals receiving anti-Tac-H produced measurable antibodies to this monoclonal antibody before day 33. Finally, there was a prolongation of graft survival in the cynomolgus heterotopic cardiac allograft model in animals receiving anti-Tac. In animals that received anti-Tac-M, the allograft survival was prolonged compared to that of the control group (mean survival, 14 +/- 1.98 days compared to 9.2 +/- 0.48 days; P less than 0.025). Graft survival was further prolonged by anti-Tac-H with a mean survival of 20.0 +/- 0.55 days (compared to controls, P less than 0.001; compared to anti-Tac-M, P less than 0.02). There was no toxicity attributable to the administration of either form of anti-Tac. Thus, anti-Tac-H significantly prolonged allograft survival in primates, without toxic side effects, and may be of value as an adjunct to standard immunosuppressive therapy in humans. | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2011577 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2011577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2011577 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2011577 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2011577 | pubmed:issn | 0027-8424 | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:GoldmanC KCK | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:JunghansR PRP | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:BenjaminW RWR | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:HakimiJJ | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:BoyerC ACA | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:BukowskaM IMI | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:DirbasF MFM | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:ParenteauG... | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:GarsiaR JRJ | lld:pubmed |
| pubmed-article:2011577 | pubmed:author | pubmed-author:QueenCC | lld:pubmed |
| pubmed-article:2011577 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2011577 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:2011577 | pubmed:volume | 88 | lld:pubmed |
| pubmed-article:2011577 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2011577 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:2011577 | pubmed:pagination | 2663-7 | lld:pubmed |
| pubmed-article:2011577 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:meshHeading | pubmed-meshheading:2011577-... | lld:pubmed |
| pubmed-article:2011577 | pubmed:year | 1991 | lld:pubmed |
| pubmed-article:2011577 | pubmed:articleTitle | Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. | lld:pubmed |
| pubmed-article:2011577 | pubmed:affiliation | Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892. | lld:pubmed |
| pubmed-article:2011577 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2011577 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2011577 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2011577 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2011577 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2011577 | lld:pubmed |
